Friday 6 November 2026 Export ELAN’s income statement to Excel — free account

Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue: +10.2%
EPS: +450.0%
Free cash flow: +35.6%
Total debt: −6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%

Follow ELAN

Alert me

Market cap: $11.8B
P/E: 0.0×
Fwd P/E: 161×
Dividend yield: —
F-score: 5/9
Altman Z: 1.28
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Elanco Animal Health Incorporated (ELAN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Elanco Animal Health Incorporated (ELAN) trades at a price to free cash flow of 33.2×. Over the past ten years it has ranged from 0.0× (December 2023) to 875× (December 2019); the current reading is higher than 67% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ELAN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Elanco Animal Health Incorporated price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ELAN/metrics/price-to-free-cash-flow">Elanco Animal Health Incorporated (ELAN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	42.9×	166.62%
FY2024	16.1×	(73.89%)
FY2023	61.6×	173.76%
FY2022	22.5×	(53.46%)
FY2021	48.3×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	27.3×	(37.88%)
FY2017	44.0×	0.00%
FY2016	44.0×	0.00%

Period	Price to free cash flow	Change
Jun 2026	34.4×	(15.29%)
Mar 2026	40.6×	(5.20%)
Dec 2025	42.9×	48.27%
Sep 2025	28.9×	38.24%
31 more quarters	Free account

Against its own ten years

Low 0.0× High 875×

Ten-year median 24.4×

Current reading's percentile 67

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
VTRS Viatris Inc. compare	10.7×
NBIX Neurocrine Biosciences, Inc. compare	15.7×
LNTH Lantheus Holdings, Inc. compare	16.9×
ALKS Alkermes plc compare	32.8×
ELAN Elanco Animal Health Incorporated	33.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Elanco Animal Health Incorporated (ELAN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ELAN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ELAN

Stockrow Weekly